Five PubMed papers for August 11–18: checkpoint-inhibitor salvage, vitiligo repigmentation, and malaria resistance

Five papers entered PubMed during the August 11, 09:00 to August 18, 09:00 (UTC-05:00) window. The ranking combines journal impact tier with an early OpenAlex cited-by snapshot retrieved on August 18. OpenAlex returned one cited-by work for the first three papers; it returned no matching work record for CHIPS or the PX1 malaria study at retrieval time. Because these papers are only days old, randomized design, sample size, endpoint strength, and clinical or research utility break the remaining ties. The citation counts are an early signal, not a stable leaderboard.

The five papers do not point to one clinical trend. They answer five different triage questions: what to use after checkpoint-inhibitor failure, how much repigmentation a systemic treatment produces, whether anesthetic choice changes recovery, whether platelets can be stored longer, and how antimalarial drug pressure is reshaping Plasmodium falciparum in Uganda.

Journal and design. LITESPARK-011 was an open-label, active-controlled phase 3 trial conducted at 184 centers in 25 countries. It enrolled 747 adults with advanced clear-cell renal cell carcinoma whose disease had progressed after anti-PD-1 or anti-PD-L1 therapy, with or without previous VEGFR tyrosine-kinase inhibition. Participants received belzutifan plus lenvatinib or cabozantinib. The dual primary endpoints were progression-free survival and overall survival. 6

Primary result. At a median follow-up of 29.0 months, median progression-free survival was 14.8 versus 10.7 months with belzutifan-lenvatinib versus cabozantinib: HR 0.70 (95% CI 0.59-0.84; one-sided P<0.0001). Overall survival was 34.9 versus 27.6 months, but the difference did not meet the prespecified significance threshold: HR 0.85 (95% CI 0.68-1.05; one-sided P=0.061). Grade 3 or higher treatment-emergent adverse events occurred in 84% versus 83% of patients, and hypertension was the most common severe event in both groups. 6

Why it matters. The trial gives clinicians a clear PFS signal for a difficult treatment setting, but the survival result remains unresolved. The practical question is therefore whether a roughly four-month median PFS gain justifies the combination's pill burden, toxicity monitoring, and cost for a given patient while overall survival is still immature or statistically inconclusive. The trial was open label, and the study is still ongoing with treatment and follow-up, so later survival analyses could change the balance.

People and funding. First author Robert J. Motzer is affiliated with Memorial Sloan Kettering Cancer Center in New York. The study was funded by Merck Sharp & Dohme, a subsidiary of Merck & Co. 6

Read the original paper on PubMed.

Journal and design. Viti-Up reports two global, multicenter, double-blind, placebo-controlled phase 3 trials conducted at 138 institutions in 18 countries. The trials enrolled 614 adults and adolescents aged 12 years or older with non-segmental vitiligo affecting the face and body. Participants were randomized 2:1 to once-daily upadacitinib 15 mg or placebo. The coprimary endpoints were at least 50% reduction in total-body vitiligo score and at least 75% reduction in facial vitiligo score at week 48. 7

Primary result. In Viti-Up-1, 19% versus 6% of participants reached the total-body endpoint and 25% versus 6% reached the facial endpoint with upadacitinib versus placebo. In Viti-Up-2, the corresponding results were 21% versus 6% and 23% versus 7%; all four comparisons had P<0.001. The trials reported no adjudicated major cardiovascular events, venous thromboembolic events, gastrointestinal perforations, active tuberculosis, lymphoma, non-melanoma skin cancer, or opportunistic infection other than herpes zoster during the 48-week double-blind period. 7

Why it matters. The result is unusually easy to interpret because the same direction appeared in two phase 3 studies and the endpoints reflect both facial and total-body disease. The absolute response rates still leave most participants below the prespecified thresholds after 48 weeks. The trial remains ongoing, and the safety window is limited relative to the long treatment courses that vitiligo often requires. Clinicians will need the full safety tables and longer follow-up before treating the response rate as a complete risk-benefit answer.

People and funding. First author Thierry Passeron is affiliated with the Centre Hospitalier Universitaire de Nice and Université Côte d'Azur, with additional affiliation to INSERM's Centre Méditerranéen de Médecine Moléculaire. The study was funded by AbbVie. The PubMed record also reports extensive author relationships with AbbVie and other dermatology companies, including employment and stock ownership for several authors. 7

Read the original paper on PubMed.

Journal and design. VITAL was a pragmatic, multicenter, open-label randomized clinical trial across 49 UK National Health Service hospitals. It randomized 2,508 adults aged 50 years or older who were scheduled for elective major noncardiac surgery to total intravenous anesthesia with propofol or volatile-based inhalational anesthesia. The primary endpoint was days alive and at home 30 days after surgery. 8

Primary result. Patients assigned to total intravenous anesthesia had a mean of 22.5 versus 22.4 days alive and at home at 30 days, corresponding to an incidence rate ratio of 1.00 (95% CI 0.99-1.02; adjusted P=0.68). The groups also showed no difference in 90-day days at home, mortality through six months, day-3 Quality of Recovery-15 scores, delirium, or major postoperative complications. Total intravenous anesthesia was associated with lower rates of thirst, hoarseness, and nausea or vomiting. Two cases of certain or probable unintentional awareness occurred, both in the total intravenous group. 8

Why it matters. The result narrows the rationale for choosing total intravenous anesthesia in older adults having major noncardiac surgery. It may still be preferable for specific airway, nausea, environmental, or workflow reasons, but this large pragmatic trial did not show a broad recovery advantage on the patient-centered primary endpoint. The trial was open label, and the anesthetic technique remained embedded in local perioperative practice rather than being tested as an isolated drug effect.

People and funding. First author Shaman Jhanji is affiliated with the Royal Marsden NHS Foundation Trust and the VITAL trial team at the University of Warwick. The official ISRCTN record names the University of Warwick as sponsor and the UK National Institute for Health and Care Research Evaluation, Trials and Studies Co-ordinating Centre as funder. 9

Read the original paper on PubMed.

Journal and design. CHIPS was a phase 3, multicenter, partially blinded, adaptive, noninferiority storage-duration trial conducted at 27 sites in the United States and Australia. It enrolled pediatric and adult patients undergoing cardiac surgery with cardiopulmonary bypass who required platelet transfusion for active bleeding. Patients were randomized 2:1 to cold-stored platelets kept for up to 21 days or room-temperature platelets kept for up to 7 days. The primary analysis included 989 of the 1,000 patients who received a transfusion. 4

Primary result. Cold-stored platelets were noninferior to room-temperature platelets for the hemostatic efficacy score, with a posterior probability above 99.9% for every tested cold-storage duration. The pooled mean difference in the bleeding score was 0.09 (95% credible interval -0.06 to 0.23). Twenty-four-hour chest-tube output was 8.9 versus 8.4 mL/kg, with a median difference of 0.4 mL/kg (95% CI -1.0 to 1.5). Thrombotic events, respiratory distress syndrome, kidney failure, septic shock, and mortality were similar; reexploration was more frequent in the cold-storage group in the reported analysis. 4

Why it matters. This is a logistics result with clinical consequences. Extending platelet storage from roughly one week to as long as 21 days could reduce wastage and make platelet inventories more usable in hospitals that cannot maintain a short room-temperature shelf life. The trial studied actively bleeding cardiac-surgery patients, so the storage policy should not be generalized automatically to every transfusion setting. The reexploration imbalance also deserves attention in the full paper and follow-up analyses.

People and funding. First author Philip C. Spinella is affiliated with the University of Pittsburgh's Departments of Surgery and Critical Care Medicine. The PubMed-indexed record does not state a grant or funding source. 4

Read the original paper on PubMed.

Journal and design. This Nature Medicine study combined population-genetic analysis, whole-genome sequencing, longitudinal genotyping, ex vivo drug-susceptibility testing, and an in-vitro gene-disruption experiment. The discovery analysis used 157 whole-genome sequences from Plasmodium falciparum in Uganda. A separate longitudinal set contained 1,436 samples with adequate sequencing coverage for haplotype prevalence analysis. 5

Primary result. The strongest recent-selection signal centered on the px1 locus rather than the better-known kelch13 mutations. The PIN haplotype, defined by three PX1 mutations and two deletions, was first observed in 2008 and reached 84% prevalence in northern Uganda and 55% in eastern Uganda by 2024. PIN-carrying parasites showed reduced ex vivo susceptibility to lumefantrine, mefloquine, and dihydroartemisinin. Disrupting px1 in vitro increased susceptibility to all three drugs, supporting a mechanistic link rather than a purely descriptive association. 5

Why it matters. The paper identifies a plausible resistance mechanism in an African parasite population under long-term artemisinin-based combination-therapy pressure. That matters for surveillance because a marker associated with reduced susceptibility can spread before clinicians see a uniform treatment-failure signal. The work is genetic and laboratory-based: it does not measure clinical treatment efficacy directly, and the clinical consequences of the PIN haplotype still require prospective therapeutic-efficacy studies.

People and funding. First author Karamoko Niaré is affiliated with Brown University; coauthors include investigators from the University of California, San Francisco, and the University of North Carolina. The PubMed record lists multiple NIH/NIAID grants, along with support from Medicines for Malaria Venture and the Bill & Melinda Gates Foundation. 10

Read the original paper in Nature Medicine or open its PubMed record.

For an oncology clinic, LITESPARK-011 is the most immediate treatment-comparison read, but the overall-survival result is still the number to watch. Viti-Up is the cleanest replicated efficacy signal, with the longest-term safety question still open. Perioperative teams can use VITAL and CHIPS for two different operational decisions: anesthetic choice did not improve broad recovery in VITAL, while cold platelet storage may expand inventory without losing hemostatic efficacy in cardiac surgery. Researchers in malaria surveillance should open the PX1 paper with its figures and supplemental methods: the important result is the convergence of population spread, drug susceptibility, and experimental perturbation.